SPRY
Income statement / Annual
Last year (2025), ARS Pharmaceuticals Inc's total revenue was $84.28 M,
a decrease of 5.46% from the previous year.
In 2025, ARS Pharmaceuticals Inc's net income was -$171.30 M.
See ARS Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$84.28 M |
$89.15 M |
$30.00 K |
$1.32 M |
$5.51 M |
$17.84 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$20.42 M
|
$20.56 M
|
$0.00
|
$17.12 M
|
$213.00 K
|
$14.07 M
|
$1.55 M
|
$1.42 M
|
| Gross Profit |
$63.86 M
|
$68.59 M
|
$30.00 K
|
-$15.80 M
|
$5.29 M
|
$3.77 M
|
-$1.55 M
|
-$1.42 M
|
| Gross Profit Ratio |
0.76
|
0.77
|
1
|
-12.01
|
0.96
|
0.21
|
0
|
0
|
| Research and Development Expenses |
$13.18 M
|
$19.58 M
|
$20.27 M
|
$18.38 M
|
$20.27 M
|
$14.07 M
|
$21.51 M
|
$14.80 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$47.28 M
|
$18.46 M
|
$4.69 M
|
$4.23 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$200.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$230.12 M
|
$0.00
|
$47.28 M
|
$18.66 M
|
$4.69 M
|
$4.23 M
|
$1.02 M
|
$2.10 M
|
| Other Expenses |
$0.00
|
$52.10 M
|
$0.00
|
-$17.32 M
|
-$213.00 K
|
-$14.07 M
|
$0.00
|
$0.00
|
| Operating Expenses |
$243.30 M
|
$71.68 M
|
$67.55 M
|
$19.71 M
|
$24.75 M
|
$4.23 M
|
$22.52 M
|
$16.90 M
|
| Cost And Expenses |
$263.73 M
|
$92.23 M
|
$67.55 M
|
$36.83 M
|
$24.96 M
|
$18.30 M
|
$24.07 M
|
$18.32 M
|
| Interest Income |
$10.67 M
|
$0.00
|
$0.00
|
$0.00
|
$800.00 K
|
$400.00 K
|
$100.00 K
|
$43.00 K
|
| Interest Expense |
$2.60 M
|
$0.00
|
$0.00
|
$0.00
|
$106.00 K
|
$29.00 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.37 M
|
$79.00 K
|
$73.00 K
|
$319.00 K
|
$213.00 K
|
$6.00 K
|
$1.55 M
|
$1.42 M
|
| EBITDA |
-$178.08 M |
-$3.00 M |
-$67.45 M |
-$35.20 M |
-$19.24 M |
-$463.00 K |
-$22.52 M |
-$16.90 M |
| EBITDA Ratio |
-2.11
|
-0.03
|
-2248.23
|
-26.75
|
-3.49
|
-0.03
|
0
|
0
|
| Operating Income Ratio |
-2.13
|
-0.03
|
-2250.67
|
-26.99
|
-3.53
|
-0.03
|
0
|
0
|
| Total Other Income/Expenses Net |
$8.07 M
|
$11.37 M
|
$13.16 M
|
$834.00 K
|
-$789.00 K
|
-$596.00 K
|
$100.00 K
|
$741.00 K
|
| Income Before Tax |
-$171.38 M
|
$8.29 M
|
-$54.37 M
|
-$34.68 M
|
-$20.24 M
|
-$1.07 M
|
-$23.97 M
|
-$17.58 M
|
| Income Before Tax Ratio |
-2.03
|
0.09
|
-1812.17
|
-26.35
|
-3.68
|
-0.06
|
0
|
0
|
| Income Tax Expense |
-$80.00 K
|
$288.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$171.30 M
|
$8.00 M
|
-$54.37 M
|
-$34.68 M
|
-$20.24 M
|
-$1.07 M
|
-$23.97 M
|
-$17.58 M
|
| Net Income Ratio |
-2.03
|
0.09
|
-1812.17
|
-26.35
|
-3.68
|
-0.06
|
0
|
0
|
| EPS |
-1.74 |
0.0825 |
-0.57 |
-0.87 |
-0.7 |
-0.0307 |
-0.72 |
-0.53 |
| EPS Diluted |
-1.74 |
0.0781 |
-0.57 |
-0.87 |
-0.7 |
-0.0307 |
-0.72 |
-0.53 |
| Weighted Average Shares Out |
$98.57 M
|
$96.94 M
|
$95.22 M
|
$39.96 M
|
$28.87 M
|
$34.70 M
|
$33.07 M
|
$33.07 M
|
| Weighted Average Shares Out Diluted |
$98.57 M
|
$102.39 M
|
$95.22 M
|
$39.96 M
|
$28.87 M
|
$34.70 M
|
$33.07 M
|
$33.07 M
|
| Link |
|
|
|
|
|
|
|
|
